Clinical Trial Update: Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. [Phase 2]

View source ↗

Summary

Phase II open-label study assessing oral nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome Positive CML

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-05-21